1-20 of 105 Search Results for

dpp

Follow your search
Access your saved searches in your account

Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Book Chapter
Series: Contributions to Nephrology
Volume: 185
Published: 26 May 2015
10.1159/000380974
EISBN: 978-3-318-05465-1
... because the patients' reduced glomerular filtration rate results in the accumulation of certain drugs and/or their metabolites. Although recommended oral antidiabetic agents for patients with CKD differ between countries, all of the currently available dipeptidyl peptidase-4 (DPP-4) inhibitors can be used...
Book Chapter
Series: Frontiers in Diabetes
Volume: 19
Published: 12 August 2008
10.1159/000152022
EISBN: 978-3-8055-8641-2
...: dipeptidyl-peptidase IV (DPP-4) inhibitors inhibit the degradation of the incretins glucagon-like peptide-1 (GLP-1) and glucosedependent insulinotropic peptide. The DPP-4 inhibitors sitagliptin and vildagliptin are orally active and have been shown to be efficacious and safe. They reduce hemoglobin A1c...
Book Chapter
Series: Chemical Immunology and Allergy
Volume: 72
Published: 05 August 1999
10.1159/000058725
EISBN: 978-3-318-00423-6
Book Chapter
Series: Endocrine Development
Volume: 32
Published: 21 August 2017
10.1159/000475730
EISBN: 978-3-318-05974-8
... of these metabolic functions has led to the notion that incretin hormones, and specifically GLP-1, would represent ideal antidiabetic treatment options. As native GLP-1 is degraded by dipeptidyl peptidase type 4 (DPP-4) within minutes, other pharmacological approaches to exploit GLP-1 actions for the treatment...
Book Chapter
Series: Frontiers of Hormone Research
Volume: 43
Published: 12 June 2014
10.1159/000360560
EISBN: 978-3-318-02674-0
... recently reported a comprehensive analysis of the adipo-vascular axis and identified more than 30 adipokines being associated with CVD [ 7 ]. In the current chapter, we decided to focus on a small selection of novel adipokines with a potentially very strong link to CVD, such as dipeptidyl peptidase (DPP)-4...
Book Chapter
Series: Endocrine Development
Volume: 31
Published: 27 January 2016
10.1159/000439372
EISBN: 978-3-318-05639-6
... dipeptidyl peptidase-IV (DPP-4), which cleaves and inactivates the peptide GLP-1 at the N-terminus [ 5 ]. Around the turn of the millennium, the physiological and pharmacological effects of GLP-1 were utilized for type 2 diabetes therapy and resulted in the introduction of two novel drug classes...
Book Chapter
Series: Frontiers of Hormone Research
Volume: 43
Published: 12 June 2014
10.1159/000360598
EISBN: 978-3-318-02674-0
... glucagon-like peptide (GLP)-1 [GLP-1(7-36) amide] and its metabolites, GLP-1 receptor (GLP-1R) agonists and analogues, and of dipeptidyl peptidase (DPP)-4 inhibitor (DPP-4i) therapies. Biology of Glucagon-Like Peptide-1 and Its Receptor GLP-1 is a peptide hormone synthesized in and secreted...
Book Chapter
Series: Monographs in Human Genetics
Volume: 21
Published: 11 September 2017
10.1159/000477277
EISBN: 978-3-318-06098-0
... by Cambio, Cambridge, UK) in cell nuclei (blue, DAPI). Overview ( a ) and detail ( b ) of sex chromosomes in an adult 40,XY* mouse. Overview ( c ) and detail ( d ) of a pubertal 41,XX Y * mouse (21 dpp), presenting 1 Y and 2 X chromosomes in the cell nuclei. The 41,XX Y * mouse model also resembles...
Book Chapter
Series: Frontiers in Diabetes
Volume: 28
Published: 03 January 2020
10.1159/000480166
EISBN: 978-3-318-06612-8
... control, and the possible perinatal, immediate, and long-term newborns consequences. Others drugs used for type 2 diabetes (i.e., glucagon-like peptide 1 receptor agonists, DPP-4 inhibitors, acarbose) could be potentially useful for the treatment of GDM. The problem is always the passage through...
Book Chapter
Series: Advances in Cardiology
Volume: 45
Published: 14 February 2008
10.1159/000115193
EISBN: 978-3-8055-8428-9
... disease. New possibilities are representedby incretin mimetic compounds, dipeptidyl peptidase (DPP)-4 inhibitors, inhaled insulinand eventually oral insulin. ...
Book Chapter
Series: Frontiers in Diabetes
Volume: 27
Published: 18 June 2019
10.1159/000486263
EISBN: 978-3-318-06507-7
..., such as dipeptidyl peptidase 4 (DPP-4) inhibitors, sodium-glucose co-transporter 2 (SGLT-2) inhibitors and glucagon-like peptide 1 (GLP-1) analogues, were used. There are 5 large randomized clinical trials that examine the impact of intensive glycaemic control on cardiovascular events in diabetes (Table 1...
Book Chapter
Series: Frontiers of Hormone Research
Volume: 43
Published: 12 June 2014
EISBN: 978-3-318-02674-0
... control: potential implications in cardiovascular disease. Atherosclerosis 2013;226:305-314. 11. Fadini GP, Avogaro A: Cardiovascular effects of DPP-4 inhibition: beyond GLP-1. Vascul Pharmacol 2011;55:10-16. 12. Ta NN, Li Y, Schuyler CA, Lopes-Virella MF, Huang Y: DPP-4 (CD26) inhibitor...
Book Chapter
Series: Contributions to Nephrology
Volume: 170
Published: 08 June 2011
10.1159/000325781
EISBN: 978-3-8055-9743-2
... was not designed to analyze specific components, patients who did vigorous leisure-time physical activities had a significantly reduced risk of diabetes [ 2 ]. The largest and most comprehensive lifestyle modification study was the US Diabetes Prevention Program (DPP) which randomized 3,234 overweight adults...
Book Chapter
Series: Endocrine Development
Volume: 32
Published: 21 August 2017
10.1159/000475731
EISBN: 978-3-318-05974-8
..., cardioprotective and anti-inflammatory effects. Experimental approaches and treatment of patients with GLP-1 analogs as well as dipeptidyl peptidase-IV (DPP-4) inhibitors, which inhibit the endopeptidase that rapidly degrades GIP and GLP-1, underscore the multiple beneficial effects mediated by GLP-1, beyond blood...
Book Chapter
Series: Contributions to Nephrology
Volume: 196
Published: 09 August 2018
EISBN: 978-3-318-06298-4
... practice. Curr Drug Metab 2011;12:57-69. 14. Chacra A, Gantz I, Mendizabal G, Durlach L, O'Neill EA, Zimmer Z, Suryawanshi S, Engel SS, Lai E: A randomised, double-blind, trial of the safety and efficacy of omarigliptin (a once-weekly DPP-4 inhibitor) in subjects with type 2 diabetes and renal...
Book
Book Cover Image
Series: Monographs in Human Genetics
Volume: 21
Published: 11 September 2017
10.1159/isbn.978-3-318-06098-0
EISBN: 978-3-318-06098-0
Book Chapter
Series: Contributions to Nephrology
Volume: 185
Published: 26 May 2015
EISBN: 978-3-318-05465-1
... and low-density lipoprotein heterogeneity following treatment of type 2 diabetes patients with the dipeptidyl peptidase-4 inhibitor, vildagliptin: a pilot study. Am J Cardiovasc Drugs 2013;13:443-450. 19. Fujita H, Taniai H, Murayama H, et al: DPP-4 inhibition with alogliptin on top of angiotensin II...
Book Chapter
Series: Medicine and Sport Science
Volume: 60
Published: 15 September 2014
10.1159/000357343
EISBN: 978-3-318-02577-4
... of which was the Diabetes Prevention Program (DPP, n = 3,234) from the United States. The length of follow-up in these studies ranged from 3 to 6 years. Goals for the lifestyle interventions typically included a sustained weight loss of 5-7%, a reduction in kilojoule, alcohol, fat and sugar intake...
Book Chapter
Series: Medicine and Sport Science
Volume: 61
Published: 16 June 2016
10.1159/000445239
EISBN: 978-3-318-03011-2
...-quality studies before 2009 are reviewed when appropriate. In addition, though exercise training responses are of the greatest importance to this review, investigations of lifestyle interventions that include exercise or support increased physical activity (e.g. Diabetes Prevention Program, DPP; Look...
Book Chapter
Series: Else Kröner-Fresenius Symposia
Volume: 4
Published: 05 June 2013
10.1159/000346539
EISBN: 978-3-318-02348-0
... by the dipeptidyl peptidase IV (DPP-IV). In contrast to native GLP-1, exendin-4, a GLP-1R agonist originally isolated from the venom of the gila monster (Heloderma suspectum) , exhibits a greatly enhanced half-life due to relative resistance to DPP-IV degradation. Accordingly, DPP-IV-resistant GLP-1 analogs...